CA2571614C - Screening methods - Google Patents

Screening methods Download PDF

Info

Publication number
CA2571614C
CA2571614C CA2571614A CA2571614A CA2571614C CA 2571614 C CA2571614 C CA 2571614C CA 2571614 A CA2571614 A CA 2571614A CA 2571614 A CA2571614 A CA 2571614A CA 2571614 C CA2571614 C CA 2571614C
Authority
CA
Canada
Prior art keywords
tau
tau protein
phosphorylation
protein
sites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2571614A
Other languages
English (en)
French (fr)
Other versions
CA2571614A1 (en
Inventor
Malcolm Ward
Helen Byers
Brian Henry Anderton
Pascal Derkinderen
Christopher Hugh Reynolds
Ritchie Williamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King's College London
Proteome Sciences PLC
Original Assignee
King's College London
Proteome Sciences PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King's College London, Proteome Sciences PLC filed Critical King's College London
Publication of CA2571614A1 publication Critical patent/CA2571614A1/en
Application granted granted Critical
Publication of CA2571614C publication Critical patent/CA2571614C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
CA2571614A 2004-06-21 2005-06-21 Screening methods Expired - Fee Related CA2571614C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58090104P 2004-06-21 2004-06-21
US60/580,901 2004-06-21
PCT/GB2005/002475 WO2005123048A2 (en) 2004-06-21 2005-06-21 Screening methods using c-abl, fyn and syk in combination with tau protein

Publications (2)

Publication Number Publication Date
CA2571614A1 CA2571614A1 (en) 2005-12-29
CA2571614C true CA2571614C (en) 2016-12-06

Family

ID=35064772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2571614A Expired - Fee Related CA2571614C (en) 2004-06-21 2005-06-21 Screening methods

Country Status (8)

Country Link
US (3) US8367360B2 (enExample)
EP (2) EP2441847B1 (enExample)
JP (3) JP5058792B2 (enExample)
AU (1) AU2005253776B8 (enExample)
CA (1) CA2571614C (enExample)
DK (1) DK1794313T3 (enExample)
ES (1) ES2415665T3 (enExample)
WO (1) WO2005123048A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019273A2 (en) * 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
DE602006004196D1 (de) * 2006-06-01 2009-01-22 Cellzome Ag Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung
US20100159477A1 (en) * 2006-07-13 2010-06-24 Peter Hornbeck Reagents for the detection of protein phosphorylation in signaling pathways
WO2008057599A2 (en) * 2006-11-10 2008-05-15 Intra-Cellular Therapies, Inc. Methods for the treatment of abeta related disorders and compositions therefor
WO2008145789A1 (es) * 2007-05-28 2008-12-04 Pontificia Universidad Catolica De Chile Uso de compuestos derivados de benzamidina metanosulfonato o su sal farmacéuticamente aceptable, por ejemplo mesilato de imatinib, para preparar un medicamento para el tratamiento de la enfermedad neurodegenerativa de niemann pick de tipo c ( npc).
WO2009143556A1 (en) * 2008-05-30 2009-12-03 The University Of Sydney TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION
WO2010118055A1 (en) 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
RU2012107457A (ru) 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
EP2485733A4 (en) * 2009-10-09 2014-06-18 Afraxis Holdings Inc METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US20130071330A1 (en) * 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
SG192596A1 (en) 2011-02-02 2013-09-30 Cognition Therapeutics Inc Isolated compounds from turmeric oil and methods of use
CA2866392C (en) 2012-03-30 2023-10-24 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
DK2844256T3 (da) * 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
EP2852388A4 (en) * 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
KR101582852B1 (ko) * 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
JP2014147365A (ja) * 2013-02-04 2014-08-21 Osaka City Univ オリゴヌクレオチド構造体および遺伝子発現抑制方法
BR112015022156A2 (pt) 2013-03-14 2017-11-14 Isis Pharmaceuticals Inc composições e métodos para modular a expressão de tau
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
JP6342627B2 (ja) * 2013-08-02 2018-06-13 国立大学法人 東京大学 筋萎縮性側索硬化症の新規病因遺伝子
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
PT3116911T (pt) * 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
EP3368032A1 (en) * 2015-10-28 2018-09-05 AB Science Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
JP2017131191A (ja) * 2016-01-29 2017-08-03 国立大学法人京都大学 疾患の予防及び／又は治療剤のスクリーニング方法
MD3519572T2 (ro) 2016-09-29 2024-03-31 Biogen Ma Inc Compuși și procedee de reducere a expresiei Tau
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
JPWO2018216705A1 (ja) * 2017-05-23 2020-03-26 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
JP7197864B2 (ja) * 2017-05-31 2022-12-28 公立大学法人名古屋市立大学 アルツハイマー病バイオマーカー
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
SG11202008895WA (en) * 2018-03-13 2020-10-29 Janssen Pharmaceutica Nv Modified oligonucleotides for use in treatment of tauopathies
CN120040470A (zh) 2018-11-20 2025-05-27 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN110702665B (zh) * 2019-11-14 2022-03-22 济南大学 一种纸基耦合增强拉曼传感器制备及其在大田软海绵酸检测中的应用
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US20260097056A1 (en) * 2022-09-20 2026-04-09 University Of Virginia Patent Foundation Syk activators and inhibitors in neurodegenerative diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5514778A (en) * 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods

Also Published As

Publication number Publication date
WO2005123048A2 (en) 2005-12-29
JP2014198054A (ja) 2014-10-23
AU2005253776A8 (en) 2012-02-02
WO2005123048A3 (en) 2006-03-30
EP2441847B1 (en) 2015-09-23
US20080103107A1 (en) 2008-05-01
DK1794313T3 (da) 2013-07-22
EP2441847A2 (en) 2012-04-18
US20130123133A1 (en) 2013-05-16
US8367360B2 (en) 2013-02-05
ES2415665T3 (es) 2013-07-26
AU2005253776A1 (en) 2005-12-29
JP5668201B2 (ja) 2015-02-12
JP5058792B2 (ja) 2012-10-24
AU2005253776B2 (en) 2011-09-29
CA2571614A1 (en) 2005-12-29
US20160186233A1 (en) 2016-06-30
AU2005253776B8 (en) 2012-02-02
EP1794313A2 (en) 2007-06-13
EP1794313B1 (en) 2013-05-15
JP2008504022A (ja) 2008-02-14
EP2441847A3 (en) 2012-07-25
JP2012024094A (ja) 2012-02-09

Similar Documents

Publication Publication Date Title
EP1794313B1 (en) Screening methods using c-abl, fyn and syk in combination with tau protein
Derkinderen et al. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase
Wang et al. The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function
Brunden et al. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
US9605054B2 (en) Composition and method for treating a tauopathy
DeBoer et al. Conventional kinesin holoenzymes are composed of heavy and light chain homodimers
Satoh et al. PLD3 is accumulated on neuritic plaques in Alzheimer’s disease brains
US20150051097A1 (en) Methods for Screening Inhibitors of Tau Phosphorylation By Casein Kinase I
Zhang et al. Parathyroid hormone initiates dynamic NHERF1 phosphorylation cycling and conformational changes that regulate NPT2A-dependent phosphate transport
Taylor et al. Tau tubulin kinases in proteinopathy
Class et al. Inventors: Malcolm Ward (Surrey, GB) Proteome Science Plc (Surrey, GB) Helen Byers (Surrey, GB) King'S College London (London, GB) Brian Henry Anderton (London, GB) Pascal Derkinderen (London, GB) Christipher Hugh Reynolds (London, GB) Ritchie Williamson (London, GB) Assignees: KING'S COLLEGE LONDON PROTEOME SCIENCES PLC
EP1687631B1 (en) Methods for identifying compounds involved in the phosphoinositide-mediated signalling and use thereof in the manufacture of medicaments
Grant The Role of CaMK1D in Alzheimer's Disease
Montalto Study of a cyclic nucleotide-mediated mechanism that could favor an antiaggregant conformation of tau protein
Taylor Understanding the role and regulation of TTBK1/2 during neurodegenerative disease progression
Cogo Investigating the role of the Roc/GTPase domain of the Parkinson's disease kinase LRRK2 in regulating protein function and activity
Ho Molecular mechanisms of LRRK2-associated neurodegeneration in Parkinson's disease
Derkinderen et al. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c
Guerreiro The role of LRRK2 in Parkinson’s disease: from function to dysfunction
Caltagarone Differential localization of Hic-5 and paxillin in the brain of Alzheimer's disease subjects

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831